NGAL can alternately mediate sunitinib resistance in renal cell carcinoma.

PURPOSE Serum NGAL is highly expressed in patients with advanced renal cancer treated with sunitinib. We investigated the role of NGAL in sunitinib resistance in renal cell carcinoma to identify potential tactics to overcome it. MATERIALS AND METHODS NGAL expression was correlated with sunitinib sensitivity. Vascular endothelial growth factor related… CONTINUE READING